Boehringer Ingelheim's latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Press release content from Business Wire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Human Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Business Wire. The AP news staff was not involved in its creation.
/PRNewswire/ -- Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was...
/PRNewswire/ -- Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was...
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Gainesville, Ga. poultry vaccine site has received carbon neutrality certification, becoming the company's first U.S. animal health manufacturing ...